Innovative New COPD Maintenance Treatment Now Available Through DirectRx Specialty Pharmacy
August 28, 2024 11:51 ET
|
DirectRx Pharmacy
DirectRx selected for exclusive distribution network for the newest and first-in-class COPD medication, Ohtuvayre by Verona Pharma
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
August 26, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...
Wellinks Integrates Virtual Pulmonary Rehabilitation Program at UMass Memorial Health for Massachusetts Residents Living with COPD
August 08, 2024 11:17 ET
|
Wellinks Inc.
NEW HAVEN, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Wellinks, a digital healthcare company offering comprehensive value-based solutions for Chronic Obstructive Pulmonary Disease (COPD) management,...
Acute Respiratory Distress Syndrome Analysis Report 2024: A $2.36 Billion Market by 2032 from $1.23 Billion in 2023
July 18, 2024 06:27 ET
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Report by Type, End User, Regions and Company Analysis 2024-2032" report has been added to ...
RS BioTherapeutics Announces Research Collaboration with University of Colorado School of Medicine
July 08, 2024 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., July 08, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases...
Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
July 03, 2024 04:00 ET
|
Pneumagen Ltd
Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of NeumifilNew preclinical...
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
May 23, 2024 07:00 ET
|
Pneumagen Ltd
Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...